The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02965300

Acronym

VOCs

Enrollment

230

Registered

2016-11-16

Start date

2016-10-31

Completion date

2017-08-31

Last updated

2016-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Disease, Lung Neoplasm

Keywords

Pulmonary lesion, Volatile Organic Compositions(VOCs)

Brief summary

The purpose of this study is to analysis the volatile organic gases(VOCs) in exhaled breath of pulmonary lesion patients and healthy controls, in order to find the difference of composition and concentration among groups.

Detailed description

Collect the exhaled gas in pulmonary lesion patients and healthy controls, using proton transfer reaction mass spectrometry to analysis the different composition and concentration of VOCs, to find the biomarker gases of distinguishing benign and malignant lesion of lung among different groups， and try to build a diagnostic model for lung lesion.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* cohort 1 : Inclusion criteria: Patients newly diagnosed with primary lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy. Age ≥ 18 years * cohort 2： Inclusion criteria： Patients diagnosed with pulmonary benign lesion by tissue biopsy or other examination. Age ≥ 18 years

Exclusion criteria

patients who have more than one type of carcinoma patients diagnosed type 2 diabetes mellitus patients diagnosed chronic renal failure patients diagnosed upper digestive tract ulcer patients who reject to sign the informed consent from * cohort 3： Healthy controls Volunteers without diagnosed lung diseases and pulmonary symptoms.

Design outcomes

Primary

Measure	Time frame	Description
Mass-to-charge Ratio	6 months	It is the measurement result of VOCs in exhaled breath using PTR-MS device.

Countries

China

Contacts

Primary ContactLiang-an Chen, MD,PHD

cla301@126.com8610-55499027

Outcome results